NasdaqGS - Nasdaq Real Time Price • USD
Neurocrine Biosciences, Inc. (NBIX)
As of 2:22 PM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 17 | 17 | 17 | 17 |
| Avg. Estimate | 1.03 | 1.24 | 4.07 | 6.36 |
| Low Estimate | 0.27 | 0.91 | 2.76 | 4.78 |
| High Estimate | 1.62 | 1.51 | 5.51 | 8.52 |
| Year Ago EPS | 0.95 | 0.82 | 2.47 | 4.07 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 24 | 23 | 26 | 26 |
| Avg. Estimate | 546.85M | 568.87M | 2.22B | 2.61B |
| Low Estimate | 532M | 553M | 2.17B | 2.32B |
| High Estimate | 581M | 619M | 2.37B | 3.78B |
| Year Ago Sales | 447.31M | -- | 1.89B | 2.22B |
| Sales Growth (year/est) | 22.30% | -- | 17.70% | 17.40% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | 0.78 | 0.97 | 1.14 | 1.01 |
| EPS Actual | 0.95 | 0.82 | 1.44 | 0.42 |
| Difference | 0.17 | -0.15 | 0.3 | -0.59 |
| Surprise % | 21.80% | -15.50% | 26.30% | -58.40% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 1.03 | 1.24 | 4.07 | 6.36 |
| 7 Days Ago | 1.03 | 1.24 | 4.06 | 6.27 |
| 30 Days Ago | 1.05 | 1.26 | 4.11 | 6.3 |
| 60 Days Ago | 1.19 | 1.31 | 4.8 | 6.29 |
| 90 Days Ago | 1.19 | 1.31 | 4.79 | 6.3 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 2 | 3 | 3 | 1 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | NBIX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 8.40% | -- | -- | 8.90% |
| Next Qtr. | 51.20% | -- | -- | 11.40% |
| Current Year | 64.80% | -- | -- | 5.80% |
| Next Year | 56.30% | -- | -- | 12.60% |
| Next 5 Years (per annum) | 18.00% | -- | -- | 11.45% |
| Past 5 Years (per annum) | 12.02% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Wedbush: Outperform to Outperform | 5/29/2024 |
| Maintains | UBS: Buy to Buy | 5/28/2024 |
| Initiated | Evercore ISI Group: Outperform | 5/14/2024 |
| Maintains | Citigroup: Neutral to Neutral | 5/3/2024 |
| Maintains | Canaccord Genuity: Buy to Buy | 5/2/2024 |
| Maintains | Guggenheim: Buy to Buy | 5/2/2024 |
Related Tickers
ITCI Intra-Cellular Therapies, Inc.
68.67
+2.13%
ALKS Alkermes plc
24.03
+2.69%
CTLT Catalent, Inc.
54.01
+0.41%
PBH Prestige Consumer Healthcare Inc.
63.60
-1.10%
PCRX Pacira BioSciences, Inc.
31.15
+2.70%
AMPH Amphastar Pharmaceuticals, Inc.
42.41
+0.19%
LNTH Lantheus Holdings, Inc.
83.83
+2.44%
TAK Takeda Pharmaceutical Company Limited
13.43
+0.56%
ELAN Elanco Animal Health Incorporated
17.77
+0.48%
LFCR Lifecore Biomedical, Inc.
5.81
-0.60%